Envoy Medical (COCH) News Today

Envoy Medical, Inc. (NASDAQ: COCH) has mixed analyst news: HC Wainwright maintained its Buy rating and $18 price target, but lowered several 2027 earnings forecasts. The estimate cuts may weigh on sentiment, while a sharper 2026 loss forecast and lower short interest offer some offset.

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $18 price target for Envoy Medical. HC Wainwright Reaffirms Buy Rating for Envoy Medical
• Positive Sentiment: The analyst raised its FY2026 EPS estimate to a loss of $2.61 per share from a previously forecast loss of $3.10, implying a smaller projected loss.
• Positive Sentiment: Short interest reportedly fell 84.4% in October, suggesting reduced bearish positioning. Envoy Medical Shares Shorted: Short Interest Down 84.4% in October
• Negative Sentiment: HC Wainwright cut its estimates for every quarter of 2027 and for FY2027. Its projected losses widened to $0.64 per share for Q1, $0.59 for Q2, $0.54 for Q3 and $0.50 for Q4; its FY2027 loss estimate increased to $2.25 per share from $1.80. It also lowered its Q4 2026 estimate to a loss of $0.64 per share from $0.60. These downward revisions point to weaker expected earnings and could pressure the stock.